Originally published on Investing
Related Alpha Scala News
BeiGene, Assembly Bio Ink $540M China HBV Deal; Shares Surge In Pre-Market
BeiGene (BGNE) and Assembly Biosciences (ASMB) have announced a new collaboration in China for Assembly’s three clinical-stage core inhibitor candidates for the treatment of chronic hepatitis B virus (HBV) infection. Shares in ASMB are surging 9% in Monday’s pre-market trading, while BGNE...